Strategies for non-invasive delivery of biologics

Journal of Drug Targeting

Volumn 20, Issue 6, 2012, Pages 481-501

  Chung, Seung Woo ^a   Hil Lal, Taslim A ^a   Byun, Youngro ^a  

^a Seoul National University   (South Korea)

Author keywords

Biologic; Drug delivery; Macromolecule; Nasal; Oral; Pulmonary

Indexed keywords

CALCITONIN; CARRIER PROTEIN; CHITOSAN; DESLORELIN; ENOXAPARIN; HUMAN GROWTH HORMONE; INSULIN; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; PENETRATION ENHANCING AGENT; POLYACRYLIC ACID; PROTEINASE INHIBITOR; PROTIRELIN; RECOMBINANT HUMAN INSULIN; TESTOSTERONE; TRANSFERRIN;

ACIDITY; ADJUVANT THERAPY; AEROSOL; CELL MEMBRANE PERMEABILITY; CHRONIC RESPIRATORY TRACT DISEASE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG STABILITY; ENZYMATIC DEGRADATION; HUMAN; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SPRAY DRYING;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; BIOLOGICAL AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MACROMOLECULAR SUBSTANCES;

EID: 84861805671     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.693499     Document Type: Review

References (262)

1. Adler M, Lee G. (1999). Stability and surface activity of lactate dehydrogenase in spray-dried trehalose. J Pharm Sci, 88, 199-208.
2. Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NF. (1995). Passive difusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci, 84, 1197-1204.
3. Al-Qadi S, Grenha A, Carrión-Recio D, Seijo B, Remuñán-López C. (2012). Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release, 157, 383-390.
4. Alabraba V, Farnsworth A, Leigh R, Dodson P, Gough SC, Smyth T. (2009). Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the frst 12 months. Diabetes Technol Ter, 11, 427-430.
5. Amet N, Wang W, Shen WC. (2010). Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release, 141, 177-182.
6. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev, 62, 59-82.
7. Ando T, Maitani Y, Yamamoto T, Takayama K, Nagai T. (1998). Nasal insulin delivery in rabbits using soybean-derived sterylglucoside and sterol mixtures as novel enhancers in suspension dosage forms. Biol Pharm Bull, 21, 862-865.
8. Andrews CW, Bennett L, Yu LX. (2000). Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res, 17, 639-644.
9. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. (2007). NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release, 121, 100-109.
10. Aspden T, Illum L, Skaugrud O. (1997a). The efect of chronic nasal application of chitosan solutions on cilia beat frequency in guinea pigs. Int J Pharm, 153:137-146.
11. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. (1997b). Chitosan as a nasal delivery system: the efect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci, 86, 509-513.
12. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89, 429-442.
13. Azarmi S, Roa WH, Löbenberg R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev, 60, 863-875.
14. Bai S, Ahsan F. (2009). Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res, 26, 539-548.
15. Bai S, Gupta V, Ahsan F. (2010). Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv, 23, 97-104.
16. Bai S, Tomas C, Ahsan F. (2007). Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci, 96, 2090-2106.
17. Bailey MM, Gorman EM, Munson EJ, Berkland C. (2008). Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir, 24, 13614-13620.
18. Balamurugan K, Ortiz A, Said HM. (2003). Biotin uptake by human intestinal and liver epithelial cells: role of the SMVT system. Am J Physiol Gastrointest Liver Physiol, 285, G73-G77.
19. Banerjee D, Flanagan PR, Cluett J, Valberg LS. (1986). Transferrin receptors in the human gastrointestinal tract. Relationship to body iron stores. Gastroenterology, 91, 861-869.
20. Banks WA. (2009). Characteristics of compounds that cross the blood-brain barrier. BMC Neurol, 9 Suppl 1, S3.
21. Bernkop-Schnürch A. (2005). Tiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev, 57, 1569-1582.
22. Bernkop-Schnürch A, Hornof M, Guggi D. (2004). Tiolated chitosans. Eur J Pharm Biopharm, 57, 9-17.
23. Bernkop-Schnürch A, Kast CE. (2001). Chemically modifed chitosans as enzyme inhibitors. Adv Drug Deliv Rev, 52, 127-137.
24. Bernkop-Schnürch A, Kast CE, Guggi D. (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release, 93, 95-103.
25. Bi R, Shao W, Wang Q, Zhang N. (2008). Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target, 16, 639-648.
26. Bi R, Shao W, Wang Q, Zhang N. (2009). Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J Biomed Nanotechnol, 5, 84-92.
27. Bies C, Lehr CM, Woodley JF. (2004). Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev, 56, 425-435.
28. Bilati U, Allémann E, Doelker E. (2005). Strategic approaches for overcoming peptide and protein instability within biodegradable nano-and microparticles. Eur J Pharm Biopharm, 59, 375-388.
29. Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T. (2007). Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J Control Release, 121, 168-175.
30. Bosquillon C, Lombry C, Préat V, Vanbever R. (2001). Infuence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release, 70, 329-339.
31. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. (2007). Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials, 28, 2233-2243.
32. Brooks H, Lebleu B, Vivès E. (2005). Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev, 57, 559-577.
33. Cázares-Delgadillo J, Ganem-Rondero A, Kalia YN. (2011). Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm, 78, 278-288.
34. Chae SY, Jang MK, Nah JW. (2005). Infuence of molecular weight on oral absorption of water soluble chitosans. J Control Release, 102, 383-394.
35. Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC. (2008). Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem, 19, 334-341.
36. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan P V, Jain SK. (2007). Efective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release, 122, 141-150.
37. Chandy T, Sharma C P. (1993). Chitosan matrix for oral sustained delivery of ampicillin. Biomaterials, 14, 939-944.
38. Chatterjee NS, Kumar CK, Ortiz A, Rubin SA, Said HM. (1999). Molecular mechanism of the intestinal biotin transport process. Am J Physiol, 277, C605-C613.
39. Chen MC, Wong HS, Lin KJ, Chen HL, Wey SP, Sonaje K, Lin YH, Chu CY, Sung HW. (2009). The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials, 30, 6629-6637.
40. Cheng WP, Tompson C, Ryan SM, Aguirre T, Tetley L, Brayden DJ. (2010). In vitro and in vivo characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes. J Control Release, 147, 289-297.
41. Chiang PC, Alsup JW, Lai Y, Hu Y, Heyde BR, Tung D. (2009). Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery. Nanoscale Res Lett, 4, 254-261.
42. Chono S, Fukuchi R, Seki T, Morimoto K. (2009). Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release, 137, 104-109.
43. Chono S, Tanino T, Seki T, Morimoto K. (2006). Infuence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofoxacin incorporated into liposomes. J Drug Target, 14, 557-566.
44. Chono S, Tanino T, Seki T, Morimoto K. (2007). Uptake characteristics of liposomes by rat alveolar macrophages: infuence of particle size and surface mannose modifcation. J Pharm Pharmacol, 59, 75-80.
45. Codrons V, Vanderbist F, Ucakar B, Préat V, Vanbever R. (2004). Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci, 93, 1241-1252.
46. Conacher M, Alexander J, Brewer JM. (2001). Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine, 19, 2965-2974.
47. Cone RA. (2009). Barrier properties of mucus. Adv Drug Deliv Rev, 61, 75-85.
48. Davis SS, Illum L. (2003). Absorption enhancers for nasal drug delivery. Clin Pharmacokinet, 42, 1107-1128.
49. Degim Z, Unal N, Essiz D, Abbasoglu U. (2004). The efect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci, 75, 2819-2827.
50. Derossi D, Joliot AH, Chassaing G, Prochiantz A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem, 269, 10444-10450.
51. Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654-1673.
52. Di Colo G, Burgalassi S, Zambito Y, Monti D, Chetoni P. (2004). Efects of diferent N-trimethyl chitosans on in vitro/in vivo ofoxacin transcorneal permeation. J Pharm Sci, 93, 2851-2862.
53. Di Colo G, Zambito Y, Zaino C. (2008). Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci, 97, 1652-1680.
54. Dressman JB, Telen K, Jantratid E. (2008). Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet, 47, 655-667.
55. du Plessis LH, Kotzé AF, Junginger HE. (2010a). Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride. Drug Deliv, 17, 399-407.
56. du Plessis LH, Lubbe J, Strauss T, Kotzé AF. (2010b). Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride. Int J Pharm, 385, 181-186.
57. Dünnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnürch A. (2011). Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm, 408, 191-199.
58. Edwards DA, Ben-Jebria A, Langer R. (1998). Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol, 85, 379-385.
59. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. (1997). Large porous particles for pulmonary drug delivery. Science, 276, 1868-1871.
60. Eppstein DA, Longenecker JP. (1988). Alternative delivery systems for peptides and proteins as drugs. Crit Rev Ter Drug Carrier Syst, 5, 99-139.
61. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. (1988). Measurement of gastrointestinal pH profles in normal ambulant human subjects. Gut, 29, 1035-1041.
62. Florea BI, Tanou M, Junginger HE, Borchard G. (2006). Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J Control Release, 110, 353-361
63. Föger F, Schmitz T, Bernkop-Schnürch A. (2006). In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials, 27, 4250-4255.
64. Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, Wolf RK. (2011). Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev, 63, 69-87.
65. Frokjaer S, Otzen DE. (2005). Protein drug stability: a formulation challenge. Nat Rev Drug Discov, 4, 298-306.
66. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem, 276, 5836-5840.
67. Gabor F, Schwarzbauer A, Wirth M. (2002). Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int J Pharm, 237, 227-239.
68. Gacesa P. (1988). Alginates. Carbohydrate Polymers, 8:161-182.
69. Gao Y, He L, Katsumi H, Sakane T, Fujita T, Yamamoto A. (2008). Improvement of intestinal absorption of water-soluble macromolecules by various polyamines: intestinal mucosal toxicity and absorption-enhancing mechanism of spermine. Int J Pharm, 354, 126-134.
70. Ge YC, Morgan RG. (1993). The efect of trypsin inhibitor on the pancreas and small intestine of mice. Br J Nutr, 70, 333-345.
71. George M, Abraham TE. (2006). Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan-a review. J Control Release, 114, 1-14.
72. Goldberg M, Gomez-Orellana I. (2003). Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov, 2, 289-295.
73. Goto T, Morishita M, Kavimandan NJ, Takayama K, Peppas NA. (2006). Gastrointestinal transit and mucoadhesive characteristics of complexation hydrogels in rats. J Pharm Sci, 95, 462-469.
74. Greenwald RB, Choe YH, McGuire J, Conover CD. (2003). Efective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev, 55, 217-250.
75. Grenha A, Seijo B, Remuñán-López C. (2005). Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 25, 427-437.
76. Hamman JH, Enslin GM, Kotzé AF. (2005). Oral delivery of peptide drugs: barriers and developments. BioDrugs, 19, 165-177.
77. Hamman JH, Stander M, Kotzé AF. (2002). Efect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm, 232, 235-242.
78. Huang YY, Wang CH. (2006). Pulmonary delivery of insulin by liposomal carriers. J Control Release, 113, 9-14.
79. Hussain A, Majumder QH, Ahsan F. (2006). Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res, 23, 138-147.
80. Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, 1326-1331.
81. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Release, 87, 187-198.
82. Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol, 56, 3-17.
83. Illum L. (2007). Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci, 96, 473-483.
84. Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res, 11, 1186-1189.
85. Jain AK, Khar RK, Ahmed FJ, Diwan PV. (2008). Efective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm, 69, 426-435.
86. Jalalipour M, Gilani K, Tajerzadeh H, Najafabadi AR, Barghi M. (2008a). Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int J Pharm, 352, 209-216.
87. Jalalipour M, Najafabadi AR, Gilani K, Esmaily H, Tajerzadeh H. (2008b). Efect of dimethyl-beta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. J Pharm Sci, 97, 5176-5185.
88. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. (2010). Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release, 142, 138-145.
89. Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, Huang Y. (2012). Goblet cell-targeting nanoparticles for oral insulin delivery and the infuence of mucus on insulin transport. Biomaterials, 33, 1573-1582.
90. Jintapattanakit A, Peungvicha P, Sailasuta A, Kissel T, Junyaprasert VB. (2010). Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. J Pharm Pharmacol, 62, 583-591.
91. Johnson KA. (1997). Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev, 26, 3-15.
92. Kamei N, Morishita M, Chiba H, Kavimandan NJ, Peppas NA, Takayama K. (2009a). Complexation hydrogels for intestinal delivery of interferon beta and calcitonin. J Control Release, 134, 98-102.
93. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. (2008). Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release, 132, 21-25.
94. Kamei N, Morishita M, Takayama K. (2009b). Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J Control Release, 136, 179-186.
95. Kang SK, Woo JH, Kim MK, Woo SS, Choi JH, Lee HG, Lee NK, Choi YJ. (2008). Identifcation of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol, 135, 210-216.
96. Kavimandan NJ, Losi E, Peppas NA. (2006). Novel delivery system based on complexation hydrogels as delivery vehicles for insulin-transferrin conjugates. Biomaterials, 27, 3846-3854.
97. Kean T, Tanou M. (2010). Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev, 62, 3-11
98. Khafagy el-S, Morishita M, Isowa K, Imai J, Takayama K. (2009a). Efect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release, 133, 103-108
99. Khafagy el-S, Morishita M, Kamei N, Eda Y, Ikeno Y, Takayama K. (2009b). Efciency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharm, 381, 49-55
100. Khafagy el-S, Morishita M, Onuki Y, Takayama K. (2007). Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev, 59, 1521-1546.
101. Khafagy el-S, Morishita M. (2012). Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev, 64, 531-539.
102. Khutoryanskiy VV. (2011). Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci, 11, 748-764.
103. Kim CY, Kim J, Han K, Kim S, Park K, Byun Y. (2007). Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys. J Toxicol Sci, 32, 411-420.
104. Kim SK, Kim K, Lee S, Park K, Park JH, Kwon IC, Choi K, Kim CY, Byun Y. (2005). Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance. J Pharm Biomed Anal, 39, 861-870.
105. Kim SK, Lee DY, Kim CY, Nam JH, Moon HT, Byun Y. (2007a). A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. J Control Release, 123, 155-163.
106. Kim SK, Lee DY, Lee E, Lee YK, Kim CY, Moon HT, Byun Y. (2007b). Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release, 120, 4-10.
107. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. (2005). Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release, 109, 299-316.
108. Kling J. (2008). Inhaled insulin's last gasp? Nat Biotechnol, Jun, p. 5.
109. Klingler C, Müller BW, Steckel H. (2009). Insulin-micro-and nanoparticles for pulmonary delivery. Int J Pharm, 377, 173-179.
110. Knowles MR, Boucher RC. (2002). Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest, 109, 571-577.
111. Kobayashi M, Xu YJ, Samejima K, Goda H, Niitsu M, Takahashi M, Hashimoto Y. (2003). Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors. Biol Pharm Bull, 26, 285-288.
112. Kobayashi S, Kondo S, Juni K. (1994). Study on pulmonary delivery of salmon calcitonin in rats: efects of protease inhibitors and absorption enhancers. Pharm Res, 11, 1239-1243.
113. Kobayashi S, Kondo S, Juni K. (1996). Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res, 13, 80-83.
114. Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. (1994). Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J Pharm Sci, 83, 863-867.
115. Kotzé AF, Tanou MM, Luebetaen HL, de Boer AG, Verhoef JC, Junginger HE. (1999). Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2). J Pharm Sci, 88, 253-257.
116. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. (2004). Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res, 21, 1119-1126.
117. Koushik K, Kompella UB. (2004). Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res, 21, 524-535.
118. Krauland AH, Guggi D, Bernkop-Schnürch A. (2006). Tiolated chitosan microparticles: a vehicle for nasal peptide drug delivery. Int J Pharm, 307, 270-277.
119. Lai SK, Wang YY, Hanes J. (2009). Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev, 61, 158-171.
120. Lam JK, Liang W, Chan HK. (2012). Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev, 64, 1-15.
121. Leader B, Baca QJ, Golan DE. (2008). Protein therapeutics: a summary and pharmacological classifcation. Nat Rev Drug Discov, 7, 21-39.
122. Lee E, Kim H, Lee IH, Jon S. (2009). In vivo antitumor efects of chitosan-conjugated docetaxel after oral administration. J Control Release, 140, 79-85.
123. Lee E, Lee J, Jon S. (2010). A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan. Bioconjug Chem, 21, 1720-1723.
124. Lee E, Lee J, Lee IH, Yu M, Kim H, Chae SY, Jon S. (2008). Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem, 51, 6442-6449.
125. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. (2006a). PEGylated glucagon-like peptide-1 displays preserved efects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia, 49, 1608-1611.
126. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC. (2005). Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem, 16, 377-382.
127. Lee VHL, Yamamoto A. (1989). Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev, 4:171-207.
128. Lee Y, Kim SH, Byun Y. (2000). Oral delivery of new heparin derivatives in rats. Pharm Res, 17, 1259-1264.
129. Lee YK, Kim SK, Lee DY, Lee S, Kim CY, Shin HC, Moon HT, Byun Y. (2006b). Efcacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release, 111, 290-298.
130. Lehr CM. (2000). Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release, 65, 19-29.
131. Lenzer J. (2006). Inhaled insulin is approved in Europe and United States. BMJ (Clinical research ed), Mar 11, p. 7537.
132. Lin CC, Metters AT. (2006). Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv Rev, 58, 1379-1408.
133. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, Sung HW. (2008). Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release, 132, 141-149.
134. Liu H, Tang R, Pan WS, Zhang Y, Liu H. (2003). Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol, 55, 1523-1529.
135. Liu L, Fishman ML, Hicks KB, Kende M. (2005). Interaction of various pectin formulations with porcine colonic tissues. Biomaterials, 26, 5907-5916.
136. Liu P, Krishnan TR. (1999). Alginate-pectin-poly-L-lysine particulate as a potential controlled release formulation. J Pharm Pharmacol, 51, 141-149.
137. Lochhead JJ, Torne RG. (2012). Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev, 64, 614-628.
138. Luessen HL, de Leeuw BJ, Langemeÿer MW, de Boer AB, Verhoef JC, Junginger HE. (1996). Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res, 13, 1668-1672.
139. Maa YF, Nguyen PA, Hsu SW. (1998). Spray-drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci, 87, 152-159.
140. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. (1999). Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res, 16, 249-254.
141. Madsen F, Peppas NA. (1999). Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials, 20, 1701-1708.
142. Mahler GJ, Esch MB, Tako E, Southard TL, Archer SD, Glahn RP, Shuler ML. (2012). Oral exposure to polystyrene nanoparticles afects iron absorption. Nat Nanotechnol, 7, 264-271.
143. Makhlof A, Fujimoto S, Tozuka Y, Takeuchi H. (2011a). In vitro and in vivo evaluation of WGA-carbopol modifed liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm, 77, 216-224.
144. Makhlof A, Tozuka Y, Takeuchi H. (2011b). Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci, 42, 445-451.
145. Makhlof A, Werle M, Tozuka Y, Takeuchi H. (2011c). A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release, 149, 81-88.
146. Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C, van Marle S, van Vliet A, Richardson PC. (2010). Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ter, 88, 243-250.
147. Marschütz MK, Caliceti P, Bernkop-Schnürch A. (2000). Design and in vivo evaluation of an oral delivery system for insulin. Pharm Res, 17, 1468-1474.
148. Marttin E, Verhoef JC, Romeijn SG, Merkus FW. (1995). Efects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res, 12, 1151-1157.
149. Massodi I, Bidwell GL 3rd, Raucher D. (2005). Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release, 108, 396-408.
150. Mastrandrea LD, Quattrin T. (2006). Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev, 58, 1061-1075.
151. Melmed RN, El-Aaser AA, Holt SJ. (1976). Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim Biophys Acta, 421, 280-288.
152. Merkus FWHM, Schipper NGM, Hermens WAJJ, Romeijn SG, Verhoef JC. (1993). Absorption Enhancers in Nasal Drug Delivery-Efcacy and Safety. J Controlled Release, 24:201-208.
153. Mi FL, Wu YY, Lin YH, Sonaje K, Ho YC, Chen CT, Juang JH, Sung HW. (2008). Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug Chem, 19, 1248-1255.
154. Minko T. (2004). Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev, 56, 491-509.
155. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. (2000). Polyarginine enters cells more efciently than other polycationic homopolymers. J Pept Res, 56, 318-325.
156. Miyake M, Minami T, Hirota M, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T. (2006a). Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids. J Control Release, 111, 27-34.
157. Miyake M, Minami T, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T. (2006b). Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption. J Control Release, 115, 130-133.
158. Morishita M, Goto T, Peppas NA, Joseph JI, Torjman MC, Munsick C, Nakamura K, Yamagata T, Takayama K, Lowman AM. (2004). Mucosal insulin delivery systems based on complexation polymer hydrogels: efect of particle size on insulin enteral absorption. J Control Release, 97, 115-124.
159. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. (2007). A novel approach using functional peptides for efcient intestinal absorption of insulin. J Control Release, 118, 177-184.
160. Morishita M, Lowman AM, Takayama K, Nagai T, Peppas NA. (2002). Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers. J Control Release, 81, 25-32.
161. Nakase I, Takeuchi T, Tanaka G, Futaki S. (2008). Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev, 60, 598-607.
162. Nemoto M, Hiki Y, Shimada K, Nakai N, Fujimoto K, Inoue S, Sakurada N, Kaneko H, Sugita M, Okabe M, Sasaki T. (2011). Novel hormonal delivery method using the ink-jet technology: application to pulmonary insulin therapies. Diabetes Technol Ter, 13, 509-517.
163. Niu M, Lu Y, Hovgaard L, Wu W. (2011). Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine, 6, 1155-1166.
164. Niven RW, Lott FD, Ip AY, Cribbs JM. (1994). Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm Res, 11, 1101-1109.
165. Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A, Fujimoto T, Yoshida K, Shimizu H, Takeuchi T, Sato A. (2008). Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug Chem, 19, 2253-2259.
166. Owens DR, Zinman B, Bolli G. (2003). Alternative routes of insulin delivery. Diabet Med, 20, 886-898.
167. Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. (2012). Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation. Int J Pharm, 422, 179-184.
168. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, Yang VC, Kim SY, Byun Y. (2010a). High antiangiogenic and low anticoagulant efcacy of orally active low molecular weight heparin derivatives. J Control Release, 148, 317-326.
169. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Moon HT, Kim CY, Byun Y. (2010b). Anticoagulant efcacy of solid oral formulations containing a new heparin derivative. Mol Pharm, 7, 836-843.
170. Patton JS. (1996). Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev, 19:3-36.
171. Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov, 6, 67-74.
172. Peppas NA, Khare AR. (1993). Preparation, Structure and Difusional Behavior of Hydrogels in Controlled-Release. Adv Drug Deliv Rev, 11:1-35.
173. Pérez C, Griebenow K. (2003). Efect of salts on lysozyme stability at the water-oil interface and upon encapsulation in poly(lactic-co-glycolic) acid microspheres. Biotechnol Bioeng, 82, 825-832.
174. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. (2007). Vitamin B12 as a carrier for the oral delivery of insulin. ChemMedChem, 2, 1717-1721.
175. Pinto-Alphandary H, Aboubakar M, Jaillard D, Couvreur P, Vauthier C. (2003). Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res, 20, 1071-1084.
176. Pistel KF, Kissel T. (2000). Efects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique. J Microencapsul, 17, 467-483.
177. Qian F, Mathias N, Moench P, Chi C, Desikan S, Hussain M, Smith RL. (2009). Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int J Pharm, 366, 218-220.
178. Ramanathan S, Pooyan S, Stein S, Prasad PD, Wang J, Leibowitz MJ, Ganapathy V, Sinko PJ. (2001). Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharm Res, 18, 950-956.
179. Rawat A, Majumder QH, Ahsan F. (2008). Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release, 128, 224-232.
180. Reese TS, Karnovsky MJ. (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol, 34, 207-217.
181. Rekha MR, Sharma CP. (2009). Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release, 135, 144-151.
182. Richardson DR. (2004). Mysteries of the transferrin-transferrin receptor 1 interaction uncovered. Cell, 116, 483-485.
183. Roberts MJ, Bentley MD, Harris JM. (2002). Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev, 54, 459-476.
184. Roger E, Lagarce F, Garcion E, Benoit JP. (2010). Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond), 5, 287-306.
185. Rosenstock J, Cefalu W T, Hollander PA, Klioze SS, Reis J, Duggan WT. (2009). Safety and efcacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. Diabetes Technol Ter, 11, 697-705.
186. Sadeghi AM, Avadi MR, Ejtemaimehr Sh, Abashzadeh Sh, Partoazar A, Dorkoosh F, Faghihi M, Rafee-Tehrani M, Junginger HE. (2009). Development of a Gas Empowered Drug Delivery system for peptide delivery in the small intestine. J Control Release, 134, 11-17.
187. Sajeesh S, Bouchemal K, Marsaud V, Vauthier C, Sharma CP. (2010a). Cyclodextrin complexed insulin encapsulated hydrogel microparticles: An oral delivery system for insulin. J Control Release, 147, 377-384.
188. Sajeesh S, Bouchemal K, Sharma C P, Vauthier C. (2010b). Surface-functionalized polymethacrylic acid based hydrogel microparticles for oral drug delivery. Eur J Pharm Biopharm, 74, 209-218.
189. Sajeesh S, Vauthier C, Gueutin C, Ponchel G, Sharma CP. (2010c). Tiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater, 6, 3072-3080.
190. Sakagami M. (2006). In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev, 58, 1030-1060.
191. Salama NN, Eddington ND, Fasano A. (2006). Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev, 58, 15-28.
192. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. (2009). Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev, 61, 115-127.
193. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Gibin S, Zambito Y, Di Colo G, Caramella C. (2007). Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm, 65, 68-77.
194. Schilling RJ, Mitra AK. (1991). Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm Res, 8, 721-727.
195. Schipper NGM, Verhoef J, Romeijn SG, Merkus, FWHM. (1992). Absorption Enhancers in Nasal Insulin Delivery and Teir Infuence on Nasal Ciliary Functioning. J Controlled Release, 21:173-185.
196. Schubert R, Jaroni H, Schoelmerich J, Schmidt KH. (1983). Studies on the mechanism of bile salt-induced liposomal membrane damage. Digestion, 28, 181-190.
197. Senel S, McClure SJ. (2004). Potential applications of chitosan in veterinary medicine. Adv Drug Deliv Rev, 56, 1467-1480.
198. Senior K. (2001). Bilosomes: the answer to oral vaccine delivery? Drug Discov Today, 6, 1031-1032.
199. Shao Z, Mitra AK. (1992). Nasal membrane and intracellular protein and enzyme release by bile salts and bile salt-fatty acid mixed micelles: correlation with facilitated drug transport. Pharm Res, 9, 1184-1189.
200. Shen WC. (2003). Oral peptide and protein delivery: unfulflled promises? Drug Discov Today, 8, 607-608.
201. Shukla A, Katare OP, Singh B, Vyas SP. (2010). M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm, 385, 47-52.
202. Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, Vyas SP. (2004). Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm, 278, 379-390.
203. Sintov AC, Levy HV, Botner S. (2010). Systemic delivery of insulin via the nasal route using a new microemulsion system: In vitro and in vivo studies. J Control Release, 148, 168-176.
204. Smart JD. (2005). The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev, 57, 1556-1568.
205. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178, 55-65.
206. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW. (2010a). Enteric-coated capsules flled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials, 31, 3384-3394.
207. Sonaje K, Lin KJ, Wey SP, Lin CK, Yeh TH, Nguyen HN, Hsu CW, Yen TC, Juang JH, Sung HW. (2010b). Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials, 31, 6849-6858.
208. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. (2009). In vivo evaluation of safety and efcacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials, 30, 2329-2339.
209. Song KH, Chung SJ, Shim CK. (2002). Preparation and evaluation of proliposomes containing salmon calcitonin. J Control Release, 84, 27-37.
210. Song KH, Chung SJ, Shim CK. (2005). Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release, 106, 298-308.
211. Staddon JM, Herrenknecht K, Smales C, Rubin LL. (1995). Evidence that tyrosine phosphorylation may increase tight junction permeability. J Cell Sci, 108 (Pt 2), 609-619.
212. Steyn D, du Plessis L, Kotzé A. (2010). Nasal delivery of recombinant human growth hormone: in vivo evaluation with Pheroid technology and N-trimethyl chitosan chloride. J Pharm Pharm Sci, 13, 263-273.
213. Su FY, Lin KJ, Sonaje K, Wey SP, Yen TC, Ho YC, Panda N, Chuang EY, Maiti B, Sung HW. (2012). Protease inhibition and absorption enhancement by functional nanoparticles for efective oral insulin delivery. Biomaterials, 33, 2801-2811.
214. Sun S, Liang N, Kawashima Y, Xia D, Cui F. (2011). Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin. Int J Nanomedicine, 6, 3049-3056.
215. Suzuki M, Machida M, Adachi K, Otabe K, Sugimoto T, Hayashi M, Awazu S. (2000). Histopathological study of the efects of a single intratracheal instillation of surface active agents on lung in rats. J Toxicol Sci, 25, 49-55.
216. Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. (2005). Spray-freeze-dried liposomal ciprofoxacin powder for inhaled aerosol drug delivery. Int J Pharm, 305, 180-185.
217. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. (2003). Mucoadhesive properties of carbopol or chitosan-coated liposomes and their efectiveness in the oral administration of calcitonin to rats. J Control Release, 86, 235-242.
218. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. (2004). Efects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res, 21, 2369-2376.
219. Tanou M, Henderson S, Kydonieus A, Elson C. (2007). N-sulfonato-N,O- carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release, 117, 171-178.
220. Tanou M, Verhoef JC, Junginger HE. (2001a). Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev, 50 Suppl 1, S91-101.
221. Tanou M, Verhoef JC, Junginger HE. (2001b). Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev, 52, 117-126.
222. Tanou MM, Kotzé AF, Scharringhausen T, Luessen HL, de Boer AG, Verhoef JC, Junginger HE. (2000). Efect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers. J Control Release, 64, 15-25.
223. Tirawong N, Nunthanid J, Puttipipatkhachorn S, Sriamornsak P. (2007). Mucoadhesive properties of various pectins on gastrointestinal mucosa: an in vitro evaluation using texture analyzer. Eur J Pharm Biopharm, 67, 132-140.
224. Tirawong N, Tongborisute J, Takeuchi H, Sriamornsak P. (2008). Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release, 125, 236-245.
225. Tompson CJ, Tetley L, Uchegbu IF, Cheng WP. (2009). The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery. Int J Pharm, 376, 46-55.
226. Torne RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd. (2008). Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience, 152, 785-797.
227. Torne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 127, 481-496.
228. Tomoda K, Ohkoshi T, Nakajima T, Makino K. (2008). Preparation and properties of inhalable nanocomposite particles: efects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces, 64, 70-76.
229. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GG. (2003). Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA, 100, 1972-1977.
230. Tuesca A, Nakamura K, Morishita M, Joseph J, Peppas N, Lowman A. (2008). Complexation hydrogels for oral insulin delivery: efects of polymer dosing on in vivo efcacy. J Pharm Sci, 97, 2607-2618.
231. Ungaro F, d'Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F, La Rotonda MI. (2009). Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release, 135, 25-34.
232. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. (2006). Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci, 28, 423-432.
233. van der Merwe SM, Verhoef JC, Verheijden JH, Kotzé A F, Junginger HE. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 58, 225-235.
234. van Drooge DJ, Hinrichs WL, Dickhof BH, Elli MN, Visser MR, Zijlstra GS, Frijlink HW. (2005). Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur J Pharm Sci, 26, 231-240.
235. Veronese FM, Pasut G. (2005). PEGylation, successful approach to drug delivery. Drug Discov Today, 10, 1451-1458.
236. Vivès E, Brodin P, Lebleu B. (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem, 272, 16010-16017.
237. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70, 735-740.
238. Wang X, Zheng C, Wu Z, Teng D, Zhang X, Wang Z, Li C. (2009). Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mater Res Part B Appl Biomater, 88, 150-161.
239. Werle M, Takeuchi H. (2009). Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int J Pharm, 370, 26-32.
240. Wheatley MA, Dent J, Wheeldon EB, Smith PL. (1988). Nasal Drug Delivery-an Invitro Characterization of Trans-Epithelial Electrical-Properties and Fluxes in the Presence or Absence of Enhancers. J Controlled Release, 8, 167-177.
241. Widera A, Kim KJ, Crandall ED, Shen WC. (2003). Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers. Pharm Res, 20, 1231-1238.
242. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. (2008). Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs, 22, 223-237.
243. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F. (2011). Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm, 412, 123-131.
244. Wood KM, Stone GM, Peppas NA. (2008). Wheat germ agglutinin functionalized complexation hydrogels for oral insulin delivery. Biomacromolecules, 9, 1293-1298.
245. Wood KM, Stone GM, Peppas NA. (2010). The efect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomater, 6, 48-56.
246. Woodley J. (2001). Bioadhesion: new possibilities for drug administration? Clin Pharmacokinet, 40, 77-84.
247. Woodley J F. (1994). Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ter Drug Carrier Syst, 11, 61-95.
248. Wu ZM, Zhou L, Guo XD, Jiang W, Ling L, Qian Y, Luo KQ, Zhang LJ. (2012). HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm, 425, 1-8.
249. Xia CQ, Wang J, Shen WC. (2000). Hypoglycemic efect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ter, 295, 594-600.
250. Yamagata T, Morishita M, Kavimandan NJ, Nakamura K, Fukuoka Y, Takayama K, Peppas NA. (2006). Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fuids. J Control Release, 112, 343-349.
251. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S. (1994). Efects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res, 11, 1496-1500.
252. Yang J, Sun H, Song C. (2012). Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. Diabetes Obes Metab, 14, 358-364.
253. Yang T, Mustafa F, Bai S, Ahsan F. (2004). Pulmonary delivery of low molecular weight heparins. Pharm Res, 21, 2009-2016.
254. Yang W, Peters JI, Williams RO 3rd. (2008). Inhaled nanoparticles-a current review. Int J Pharm, 356, 239-247.
255. Yeo LY, Friend JR, McIntosh MP, Meeusen EN, Morton DA. (2010). Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv, 7, 663-679.
256. Yin L, Ding J, He C, Cui L, Tang C, Yin C. (2009). Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials, 30, 5691-5700.
257. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. (2007). Evaluation of therapeutic potentials of site-specifc PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol, 73, 84-93.
258. Zhang J, Wu L, Chan HK, Watanabe W. (2011a). Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev, 63, 441-455.
259. Zhang N, Ping QN, Huang GH, Xu W F. (2005a). Investigation of lectin-modifed insulin liposomes as carriers for oral administration. Int J Pharm, 294, 247-259.
260. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. (2008). Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm, 68, 526-534.
261. Zhang Y, Wei W, Lv P, Wang L, Ma G. (2011b). Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur J Pharm Biopharm, 77, 11-19.
262. Zhang YJ, Ma CH, Lu WL, Zhang X, Wang XL, Sun JN, Zhang Q. (2005b). Permeation-enhancing efects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin, 26, 1402-1408.